Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use VYVGART HYTRULO safely and effectively. See full prescribing information for VYVGART HYTRULO. VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) injection, for subcutaneous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive chronic inflammatory demyelinating polyneuropathy (CIDP)
- generic_name
- efgartigimod alfa and hyaluronidase (human recombinant)
- product_names
- efgartigimod alfa and hyaluronidase (human recombinant)
- ndc
- 73475-3102, 73475-1221, 73475-3102-3, 73475-1221-1, 73475-1221-4
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en